Date: Monday, June 3, 2019
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall C & D
*Purpose: Although immunoglobulin A nephropathy (IgAN) is associated with a high risk of renal allograft failure, evidences for its treatment, including renin-angiotensin-aldosterone system blockade (RAASB) usage, remain limited.
*Methods: In this bi-center retrospective cohort study, we included patients who were recently diagnosed with IgAN in allograft biopsies. We identified their 6-month antihypertensive medication prescriptions and investigated the association between the medication types, albuminuria changes, and consequent 5-year death-censored-graft-failure (DCGF). The mixed effect model and cox regression analysis were used.
*Results: A total of 464 allograft IgAN patients were included; consisting of 272, 38, 33, and 121 patients in the no medication, single agent RAASB, single agent beta blocker (BB)/calcium channel blocker (CCB), and combination therapy groups, respectively. High-degree albuminuria after 6 months was an important prognostic parameter and a partial mediator for the association between the subgroups and 5-year DCGF. The usage of single RAASB was associated with decrement of albuminuria from allograft diagnosis (P for interaction = 0.03). The single BB/CCB group demonstrated significantly worse prognosis than the single RAASB group (adjusted hazard ratio, 2.76 [1.09-6.98]; P=0.03).
*Conclusions: In conclusion, RAASB may be beneficial for graft prognosis in early allograft IgAN patients who require single antihypertensive medication therapy, by means of reducing albuminuria.
To cite this abstract in AMA style:Park S, Baek C, Yu M, Kim Y, Moon J, Go H, Kim Y, Lee J, Min S, Ha J, Moon K, Kim Y, Ahn C, Park S, Lee H. Beneficial Association between Renin-Angiotensin-Aldosterone-System Blockade Usage and Graft Prognosis in Allograft Immunoglobulin A Nephropathy [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/beneficial-association-between-renin-angiotensin-aldosterone-system-blockade-usage-and-graft-prognosis-in-allograft-immunoglobulin-a-nephropathy/. Accessed June 12, 2021.
« Back to 2019 American Transplant Congress